Which Starter Dose Fits Your Weight Management Goals?
Mounjaro or Wegovy Starter Dose: Understanding Your Options
When comparing Mounjaro or Wegovy starter doses, the key difference lies in their dosing schedules and mechanisms of action. Wegovy begins with a 0.25mg dose for weeks 1-4, designed to help your body adjust to semaglutide's GLP-1 receptor activation gradually. This starter phase may help reduce initial side effects like nausea whilst your appetite regulation systems adapt. Mounjaro follows a different titration approach, starting at 2.5mg weekly for four weeks before escalating to 5mg, reflecting tirzepatide's dual GIP and GLP-1 receptor agonist profile.
The starter dose phase is crucial for both treatments, as it establishes your body's tolerance and helps predict how you'll respond to higher maintenance doses. Neither Wegovy nor Mounjaro allows dose-skipping during this initial period, as the gradual escalation is designed for both safety and effectiveness. Your prescriber will determine which starter approach aligns better with your medical history, current medications, and weight management goals. Both treatments require ongoing medical supervision throughout the dose escalation period.
Pricing Transparency: Mounjaro or Wegovy Starter Costs
Wegovy's starter dose (0.25mg) costs £79.99 at EverydayMeds, with new customers applying code FIRST40 at checkout and returning patients using DOSE25. Our Intro Duo bundle combines the first two doses (0.25mg and 0.5mg) for £169.99, providing your first two months of treatment in one convenient order. For those preferring to take the initial dose slowly, our Gentle Start Trio includes two 0.25mg pens plus one 0.5mg pen for £269.99. This pricing structure reflects the complexity of cold-chain storage and the prescription-only nature of these treatments.
Mounjaro pricing follows a different structure due to its distinct dosing schedule, though both treatments represent significant investments in long-term weight management. When comparing Mounjaro or Wegovy starter costs, consider the total treatment pathway rather than just initial pricing, as maintenance doses and long-term commitment vary between the treatments. Both medications are available through our streamlined prescriber review process, with standard 3-working-day assessment or express 24-hour review options. The investment in either starter dose reflects the sophisticated manufacturing, storage, and clinical oversight required for these prescription-only medicines.
Clinical Evidence: Mounjaro or Wegovy Starter Dose Research
The STEP trial programme established Wegovy's starter dose protocol, with STEP 1 demonstrating that patients taking semaglutide alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks versus 2.4% with placebo (Wilding et al., NEJM, 2021). The 0.25mg starter dose proved essential for tolerability, with most patients successfully progressing through the full escalation schedule. STEP 5 confirmed that this gradual approach supported sustained results, with approximately 15.2% weight reduction maintained over two years.
Mounjaro's clinical development followed a different pathway, with the SURMOUNT trials evaluating tirzepatide's dual receptor approach starting from its 2.5mg initial dose. Both treatment programmes demonstrate that starter dose adherence significantly influences long-term outcomes, making the choice between Mounjaro or Wegovy starter protocols an important clinical decision. The evidence suggests that patients who complete the starter phase successfully are more likely to achieve meaningful weight reduction during maintenance therapy.
How Wegovy Works: Mounjaro or Wegovy Mechanism Differences
Wegovy operates as a GLP-1 receptor agonist, mimicking your body's natural incretin hormone that regulates blood sugar and appetite after meals. The 0.25mg starter dose begins activating these receptors gradually, potentially reducing appetite and promoting feelings of fullness after smaller portions. This mechanism works on brain appetite centres, particularly in the hypothalamus, where hunger and satiety signals are processed. As the dose escalates over 16 weeks, the GLP-1 activation intensifies, which may lead to more pronounced appetite suppression and food craving reduction. Unlike Mounjaro's dual GIP and GLP-1 approach, Wegovy focuses specifically on GLP-1 pathways, providing a well-researched single-target mechanism for weight management support alongside lifestyle modifications.
Ordering Process: Getting Your Mounjaro or Wegovy Starter Dose
Starting either treatment begins with our comprehensive 3-minute online clinical assessment, designed to evaluate your suitability for Mounjaro or Wegovy starter doses. Our registered prescribers review your medical history, current medications, previous weight management attempts, and any contraindications within 3 working days (or 24 hours with express review). Once approved, your starter dose ships via next-day cold-chain delivery, maintaining the 2-8°C temperature requirements essential for medication stability. The process includes detailed injection guidance, side effect monitoring instructions, and clear escalation schedules whether you're beginning Wegovy's 0.25mg dose or Mounjaro's 2.5mg starter. All treatments are supplied from our GPhC-registered pharmacy (#9012878) with full regulatory compliance and ongoing clinical support throughout your treatment journey.
Storage and Practical Considerations: Mounjaro or Wegovy Starter Handling
Both treatments require refrigerated storage at 2-8°C before first use, but Wegovy offers superior room temperature stability with 6 weeks below 30°C compared to Mounjaro's 21-day limit. This storage advantage makes Wegovy more practical for travel or temporary storage situations during your starter dose phase. Both medications use pre-filled injection pens (Wegovy's FlexTouch and Mounjaro's KwikPen), designed for once-weekly self-administration with minimal preparation required. The injection technique remains consistent throughout dose escalation, so mastering the process during your starter dose prepares you for the entire treatment course. Neither treatment should be frozen, shaken vigorously, or exposed to direct sunlight, and both should be inspected for particles or discolouration before each injection.
Mounjaro or Wegovy Starter Dose: First Month Expectations
Your first month on either treatment sets the foundation for long-term success, with most patients experiencing initial appetite changes and potential mild gastrointestinal effects during the starter dose period. Wegovy's 0.25mg starting dose typically produces gentler initial effects compared to Mounjaro's higher 2.5mg starter, though individual responses vary significantly. Many patients report reduced food cravings and earlier satiety during meals within the first two weeks, though dramatic weight changes are uncommon during the starter phase. Managing expectations during this period is crucial, as the starter dose is designed for tolerance building rather than maximum therapeutic effect.
The choice between Mounjaro or Wegovy starter doses often depends on your tolerance for potential side effects and preference for dose escalation speed. Both treatments require patience during the initial weeks, as your body adjusts to the hormonal changes affecting appetite regulation. Staying hydrated, eating smaller portions, and avoiding high-fat meals can help minimize startup side effects with either treatment. Your prescriber may recommend slowing the escalation if you experience persistent nausea or other tolerance issues during the starter dose phase.
Making Your Decision: Mounjaro or Wegovy Starter Dose Selection
Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which starter dose approach aligns with your specific needs and medical profile. Consider factors like travel requirements (Wegovy's storage advantage), tolerance for side effects (Wegovy's lower starter dose), and long-term treatment goals when making your decision. The clinical evidence supports both approaches, though the mechanisms differ significantly between single GLP-1 activation and dual GIP/GLP-1 targeting. Your choice should be based on clinical consultation rather than price alone, as both treatments represent long-term commitments requiring ongoing medical supervision. Visit our Wegovy starter dose page to begin your clinical assessment, or discuss both options during your prescriber consultation. Remember to apply discount code FIRST40 for new customers or DOSE25 for returning patients at checkout, and take advantage of our next-day cold-chain delivery from our GPhC-registered pharmacy #9012878.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
